Dr. Cosme Ordo?ez Appointed Head of Investment Banking
NEW YORK, March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed Dr. Cosme Ordo?ez to the role of Head of Investment Banking, Investment Banking Principal and bolstering the firm's coverage in the healthcare sector.
Dominari Holdings Logo (PRNewsfoto/Dominari Holdings Inc.)
Dr. Ordo?ez has more than 20 years of investment banking and healthcare experience. Most recently, he served as Senior Managing Director, Investment Banking at Aegis Capital in its private equity group.
Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "We are thrilled to welcome Cosme to the firm to head up our investment banking practice. Over the course of his distinguished career, he has gained extensive experience with corporate finance activities, financial advisory services and capital raising having managed a portfolio in excess of $100 million and raised nearly a billion dollars in capital for life science companies. Furthermore, with his medical scientific background, Dr. Ordo?ez will be a tremendous asset to our clients in healthcare. We are pleased to welcome Cosme to Dominari."
Dr. Cosme Ordo?ez
Dr. Ordo?ez began his career as a Doctor of Medicine at the National Institute of Oncology in Havana, Cuba where he researched the amplification of oncogenes in breast cancer. With deep industry knowledge, he transitioned to investment banking more than 20 years ago as a healthcare analyst at Versant Partners, which was later acquired by Cantor Fitzgerald. Most recently, at Aegis Capital, he acted as the lead investment banker in multiple private placement transactions and as the Manager of a portfolio of investments in private equity valued at more than $100 million.
Over the course of his career, Dr. Ordo?ez has acted as the lead investment banker in multiple transactions, leading deal origination, due diligence, corporate finance advisory, valuation modeling, syndication and deal execution through sales and marketing efforts in collaboration with equity capital markets desks. Dr. Ordo?ez was the co-founder of Ciclofilin Pharmaceuticals, a startup biotech based in San Diego, which was acquired in 2016. Prior to founding Ciclofilin Pharma, Dr. Ordo?ez worked on the buy-side as Director of Healthcare Investments at Difference Capital, a venture capital and merchant bank, where he participated in investment decisions for a portfolio of international private and public healthcare companies. Previously, he was a senior biotechnology analyst at two other independent Canadian investment dealers, where he achieved top rankings for perceived quality of research by Brendan Wood International and Starmine.
Dr. Ordo?ez has a Doctor in Medicine degree, a Ph.D. in Experimental Medicine and Biochemistry from McGill University. He also completed a Post-Doctoral Fellowship at the Karolinska Institute in Stockholm, Sweden. Dr. Ordo?ez has published scientific manuscripts in the areas of oncology, virology and immunology. He currently holds Series 79, 7, 86 and 87 FINRA licenses.
Dominari Securities LLC, a principal subsidiary of Dominari Holdings Inc., is a dynamic, forward-thinking financial services company that seeks to create wealth for all stakeholders by capitalizing on emerging trends in the financial services sector and identifying early-stage future opportunities that are expected to generate a high rate of return for investors.
Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC. Securities brokerage, investment adviser and other non-bank deposit investments are not FDIC insured and may lose some or all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at https://brokercheck.finra.org. Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
